Last reviewed · How we verify
KLN-1010
At a glance
| Generic name | KLN-1010 |
|---|---|
| Sponsor | Kelonia Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KLN-1010 CI brief — competitive landscape report
- KLN-1010 updates RSS · CI watch RSS
- Kelonia Therapeutics, Inc. portfolio CI